At the National Cancer Center Hospital East (Kashiwa, Japan), we conducted a phase I clinical trial of GPC3 peptide vaccines in a cohort comprising 33 cases of advanced HCC from February 2007 to November 2009 (UMIN Clinical Trials Registry: 000001395) (Table 1) (30, 38). Here, GPC3 is linked to hepatocellular carcinoma.